A series of sulfenamide and sulfonamide derivatives was synthesized and evaluated for the affinity at CB1and CB2receptors. The N-bornyl-S-(5,6-di-p-tolylpyridazin-3-yl)-sulfenamide, compound 11, displayed good affinity and high selectivity for CB1receptors (Kivalues of 44.6 nM for CB1receptors and >40 μM for CB2receptors, respectively). The N-isopinocampheyl-sulfenamide 12 and its sulfonamide analogue 22 showed similar selectivity for CB1receptors with Kivalues of 75.5 and 73.2 nM, respectively. These novel compounds behave as antagonists/inverse agonists at CB1receptor in the [35S]-GTPγS binding assays, and none showed adequate predictive blood–brain barrier permeation, exhibiting low estimated LD50. However, testing compound 12 in a supraspinal analgesic test (hot-plate) revealed that it was as effective as the classic CB1receptor antagonist rimonabant, in reversing the analgesic effect of a cannabinoid agonist.

Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1receptor ligand antagonists

Cichero, Elena;Fossa, Paola;
2018

Abstract

A series of sulfenamide and sulfonamide derivatives was synthesized and evaluated for the affinity at CB1and CB2receptors. The N-bornyl-S-(5,6-di-p-tolylpyridazin-3-yl)-sulfenamide, compound 11, displayed good affinity and high selectivity for CB1receptors (Kivalues of 44.6 nM for CB1receptors and >40 μM for CB2receptors, respectively). The N-isopinocampheyl-sulfenamide 12 and its sulfonamide analogue 22 showed similar selectivity for CB1receptors with Kivalues of 75.5 and 73.2 nM, respectively. These novel compounds behave as antagonists/inverse agonists at CB1receptor in the [35S]-GTPγS binding assays, and none showed adequate predictive blood–brain barrier permeation, exhibiting low estimated LD50. However, testing compound 12 in a supraspinal analgesic test (hot-plate) revealed that it was as effective as the classic CB1receptor antagonist rimonabant, in reversing the analgesic effect of a cannabinoid agonist.
File in questo prodotto:
File Dimensione Formato  
BMC 2018, 26, 295-3071Murineddu.pdf

accesso chiuso

Descrizione: testo
Tipologia: Documento in versione editoriale
Dimensione 2.67 MB
Formato Adobe PDF
2.67 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/888053
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact